Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine.

This study investigates the behavior and effects of N-methylnaltrexone (MNTX), an opioid antagonist, on gastrointestinal functions in horses under different conditions, namely alone and when combined with morphine. The results suggest that MNTX can help reduce some of the side effects of opioid usage in horses by increasing fecal production and regulating intestinal activity.

Research Methodology

• The experiment involved five healthy adult horses.
• Morphine antagonist N-Methylnaltrexone (MNTX) was administered to these horses at different doses and under various conditions. The researchers wanted to determine its pharmacokinetics (how the drug behaves in the horse’s body).
• Serial blood samples were collected to determine these pharmacokinetics.
• A dosage of MNTX was administered alone at a dosage of 0.75 mg/kg, intravenously, twice a day for four days. This was to evaluate the effect of MNTX on the gastrointestinal tract when administered alone.
• Subsequently, MNTX and morphine were administered concurrently for six days, to find out how MNTX functions when it is accompanied by morphine.

Findings

• The study found that the pharmacokinesis of MNTX best aligned with a two-compartment model. The determined volumes of distribution, half-life, and clearance values were specified.
• No adverse effects were observed at doses equal to or less than 1 mg/kg.
• The research found that the administration of MNTX alone increased the daily weight of horse feces.
• When administered along with morphine, MNTX helped mitigate the effects of morphine on the gastrointestinal tract. It resulted in an increase in defecation frequency, fecal weight, fecal moisture content, borborygmus score (intestinal sounds), and prevented an increase in intestinal transit time (time taken for food to pass through the digestive tract).

Conclusion

• The conclusion states that since MNTX does not cross the blood-brain barrier, it would not alter the pain-relieving effects of opioids.
• This means that MNTX could counteract the negative gastrointestinal effects associated with the use of opioids in horses, potentially making it a useful substance in veterinary medicine – particularly for equine patients on opioids.